Multiple roles of HDAC inhibition in neurodegenerative conditions

被引:545
作者
Chuang, De-Maw [1 ]
Leng, Yan [1 ]
Marinova, Zoya [1 ]
Kim, Hyeon-Ju [1 ]
Chiu, Chi-Tso [1 ]
机构
[1] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HISTONE DEACETYLASE INHIBITORS; SPINAL MUSCULAR-ATROPHY; SUBEROYLANILIDE HYDROXAMIC ACID; PROTECTS DOPAMINERGIC-NEURONS; INCREASES SMN EXPRESSION; BDNF GENE-TRANSCRIPTION; TRANSGENIC MOUSE MODEL; HEAT-SHOCK-PROTEIN; VALPROIC ACID; HUNTINGTONS-DISEASE;
D O I
10.1016/j.tins.2009.06.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation in histones and other proteins and in regulating fundamental cellular activities such as transcription. A wide range of brain disorders are associated with imbalances in protein acetylation levels and transcriptional dysfunctions. Treatment with various HDAC inhibitors can correct these deficiencies and has emerged as a promising new strategy for therapeutic intervention in neurodegenerative disease. Here, we review and discuss intriguing recent developments in the use of HDAC inhibitors to combat neurodegenerative conditions in cellular and disease models. HDAC inhibitors have neuroprotective, neurotrophic and anti-inflammatory properties; improvements in neurological performance, learning/memory and other disease phenotypes are frequently seen in these models. We discuss the targets and mechanisms underlying these effects of HDAC inhibition and comment on the potential for some HDAC inhibitors to prove clinically effective in the treatment of neurodegenerative disorders.
引用
收藏
页码:591 / 601
页数:11
相关论文
共 104 条
  • [1] Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
    Abe, Ted
    Zukin, R. Suzanne
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (01) : 57 - 64
  • [2] The GDNF family: Signalling, biological functions and therapeutic value
    Airaksinen, MS
    Saarma, M
    [J]. NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) : 383 - 394
  • [3] Phenylbutyrate increases SMN expression in vitro:: relevance for treatment of spinal muscular atrophy
    Andreassi, C
    Angelozzi, C
    Tiziano, FD
    Vitali, T
    De Vincenzi, E
    Boninsegna, A
    Villanova, M
    Bertini, E
    Pini, A
    Neri, G
    Brahe, C
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (01) : 59 - 65
  • [4] Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy
    Avila, Amy M.
    Burnett, Barrington G.
    Taye, Addis A.
    Gabanella, Francesca
    Knight, Melanie A.
    Hartenstein, Parvana
    Cizman, Ziga
    Di Prospero, Nicholas A.
    Pellizzoni, Livio
    Fischbeck, Kenneth H.
    Sumner, Charlotte J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (03) : 659 - 671
  • [5] Beyond transcription factors: The role of chromatin modifying enzymes in regulating transcription required for memory
    Barrett, Ruth M.
    Wood, Marcelo A.
    [J]. LEARNING & MEMORY, 2008, 15 (07) : 460 - 467
  • [6] DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS
    Bartsch, O
    Schmidt, S
    Richter, M
    Morlot, S
    Seemanová, E
    Wiebe, G
    Rasi, S
    [J]. HUMAN GENETICS, 2005, 117 (05) : 485 - 493
  • [7] Differential contributions of Caenorhabditis elegans histone deacetylases to Huntingtin polyglutamine toxicity
    Bates, EA
    Victor, M
    Jones, AK
    Shi, Y
    Hart, AC
    [J]. JOURNAL OF NEUROSCIENCE, 2006, 26 (10) : 2830 - 2838
  • [8] Bim is a direct target of a neuronal E2F-dependent apoptotic pathway
    Biswas, SC
    Liu, DX
    Greene, LA
    [J]. JOURNAL OF NEUROSCIENCE, 2005, 25 (37) : 8349 - 8358
  • [9] Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients
    Brahe, C
    Vitali, T
    Tiziano, FD
    Angelozzi, C
    Pinto, AM
    Borgo, F
    Moscato, U
    Bertini, E
    Mercuri, E
    Neri, G
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (02) : 256 - 259
  • [10] Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
    Brichta, L
    Hofmann, Y
    Hahnen, E
    Siebzehnrubl, FA
    Raschke, H
    Blumcke, I
    Eyupoglu, IY
    Wirth, B
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (19) : 2481 - 2489